Human methylome studies SRP259185 Track Settings
 
Multi-omics analysis reveals divergent epigenetic regulation of gene expression and drivers of esophageal squamous cell carcinoma (WGBS) [Adjacent Normal Esophageal, Esophageal Squamouse Carcinoma]

Track collection: Human methylome studies

+  All tracks in this collection (463)

Maximum display mode:       Reset to defaults   
Select views (Help):
AMR       HMR       CpG methylation ▾       PMD       CpG reads ▾      
Select subtracks by views and experiment:
 All views AMR  HMR  CpG methylation  PMD  CpG reads 
experiment
SRX8208800 
SRX8208801 
SRX8208802 
SRX8208803 
SRX8208804 
SRX8208805 
SRX8208806 
SRX8208807 
SRX8208808 
SRX8208809 
SRX8208810 
SRX8208812 
SRX8208813 
SRX8208814 
SRX8208815 
SRX8208816 
SRX8208817 
SRX8208818 
SRX8208819 
List subtracks: only selected/visible    all    ()
  experiment↓1 views↓2   Track Name↓3  
hide
 SRX8208802  HMR  Adjacent Normal Esophageal / SRX8208802 (HMR)   Schema 
hide
 Configure
 SRX8208800  CpG methylation  Esophageal Squamouse Carcinoma / SRX8208800 (CpG methylation)   Schema 
hide
 SRX8208803  HMR  Adjacent Normal Esophageal / SRX8208803 (HMR)   Schema 
hide
 Configure
 SRX8208801  CpG methylation  Esophageal Squamouse Carcinoma / SRX8208801 (CpG methylation)   Schema 
hide
 SRX8208804  HMR  Adjacent Normal Esophageal / SRX8208804 (HMR)   Schema 
hide
 Configure
 SRX8208802  CpG methylation  Adjacent Normal Esophageal / SRX8208802 (CpG methylation)   Schema 
hide
 SRX8208805  HMR  Adjacent Normal Esophageal / SRX8208805 (HMR)   Schema 
hide
 Configure
 SRX8208803  CpG methylation  Adjacent Normal Esophageal / SRX8208803 (CpG methylation)   Schema 
hide
 SRX8208806  HMR  Adjacent Normal Esophageal / SRX8208806 (HMR)   Schema 
hide
 Configure
 SRX8208804  CpG methylation  Adjacent Normal Esophageal / SRX8208804 (CpG methylation)   Schema 
hide
 SRX8208807  HMR  Adjacent Normal Esophageal / SRX8208807 (HMR)   Schema 
hide
 Configure
 SRX8208805  CpG methylation  Adjacent Normal Esophageal / SRX8208805 (CpG methylation)   Schema 
hide
 SRX8208808  HMR  Adjacent Normal Esophageal / SRX8208808 (HMR)   Schema 
hide
 Configure
 SRX8208806  CpG methylation  Adjacent Normal Esophageal / SRX8208806 (CpG methylation)   Schema 
hide
 SRX8208809  HMR  Adjacent Normal Esophageal / SRX8208809 (HMR)   Schema 
hide
 Configure
 SRX8208807  CpG methylation  Adjacent Normal Esophageal / SRX8208807 (CpG methylation)   Schema 
hide
 SRX8208810  HMR  Adjacent Normal Esophageal / SRX8208810 (HMR)   Schema 
hide
 Configure
 SRX8208808  CpG methylation  Adjacent Normal Esophageal / SRX8208808 (CpG methylation)   Schema 
hide
 Configure
 SRX8208809  CpG methylation  Adjacent Normal Esophageal / SRX8208809 (CpG methylation)   Schema 
hide
 SRX8208812  HMR  Esophageal Squamouse Carcinoma / SRX8208812 (HMR)   Schema 
hide
 Configure
 SRX8208810  CpG methylation  Adjacent Normal Esophageal / SRX8208810 (CpG methylation)   Schema 
hide
 SRX8208813  HMR  Esophageal Squamouse Carcinoma / SRX8208813 (HMR)   Schema 
hide
 SRX8208814  HMR  Esophageal Squamouse Carcinoma / SRX8208814 (HMR)   Schema 
hide
 Configure
 SRX8208812  CpG methylation  Esophageal Squamouse Carcinoma / SRX8208812 (CpG methylation)   Schema 
hide
 SRX8208819  HMR  Esophageal Squamouse Carcinoma / SRX8208819 (HMR)   Schema 
hide
 Configure
 SRX8208813  CpG methylation  Esophageal Squamouse Carcinoma / SRX8208813 (CpG methylation)   Schema 
hide
 Configure
 SRX8208814  CpG methylation  Esophageal Squamouse Carcinoma / SRX8208814 (CpG methylation)   Schema 
hide
 Configure
 SRX8208815  CpG methylation  Esophageal Squamouse Carcinoma / SRX8208815 (CpG methylation)   Schema 
hide
 Configure
 SRX8208816  CpG methylation  Esophageal Squamouse Carcinoma / SRX8208816 (CpG methylation)   Schema 
hide
 Configure
 SRX8208817  CpG methylation  Esophageal Squamouse Carcinoma / SRX8208817 (CpG methylation)   Schema 
hide
 Configure
 SRX8208818  CpG methylation  Esophageal Squamouse Carcinoma / SRX8208818 (CpG methylation)   Schema 
hide
 Configure
 SRX8208819  CpG methylation  Esophageal Squamouse Carcinoma / SRX8208819 (CpG methylation)   Schema 
    

Study title: Multi-omics analysis reveals divergent epigenetic regulation of gene expression and drivers of esophageal squamous cell carcinoma (WGBS)
SRA: SRP259185
GEO: GSE149608
Pubmed: 32699215

Experiment Label Methylation Coverage HMRs HMR size AMRs AMR size PMDs PMD size Conversion Details
SRX8208800 Esophageal Squamouse Carcinoma 0.549 16.2 49176 13810.0 191587 9592.0 2246 677647.6 0.994 title: GSM4505874 Tumor T13 WGBS, Homo sapiens, Bisulfite-Seq; {"source_name": "Esophageal Squamouse carcinoma", "tissue": "esophageal squamouse carcinoma", "tumor_pathological_stage": "moderately or poorly differentiated", "tnm_stage": "T11N0M0"}
SRX8208801 Esophageal Squamouse Carcinoma 0.519 17.7 21052 27279.8 180124 10044.8 2118 755517.2 0.992 title: GSM4505875 Tumor T15 WGBS, Homo sapiens, Bisulfite-Seq; {"source_name": "Esophageal Squamouse carcinoma", "tissue": "esophageal squamouse carcinoma", "tumor_pathological_stage": "moderately differentiated", "tnm_stage": "T1bN0M0"}
SRX8208802 Adjacent Normal Esophageal 0.736 18.7 41272 1164.4 115839 2830.6 2866 9755.7 0.995 title: GSM4505856 normal N1 WGBS, Homo sapiens, Bisulfite-Seq; {"source_name": "Adjacent normal tissue", "tissue": "adjacent normal esophageal tissue", "tumor_pathological_stage": "NA", "tnm_stage": "NA"}
SRX8208803 Adjacent Normal Esophageal 0.724 17.6 40713 1181.3 119772 2813.5 2607 12538.7 0.994 title: GSM4505857 normal N2 WGBS, Homo sapiens, Bisulfite-Seq; {"source_name": "Adjacent normal tissue", "tissue": "adjacent normal esophageal tissue", "tumor_pathological_stage": "NA", "tnm_stage": "NA"}
SRX8208804 Adjacent Normal Esophageal 0.724 17.2 40256 1168.2 113721 3070.0 2814 10078.3 0.994 title: GSM4505858 normal N6 WGBS, Homo sapiens, Bisulfite-Seq; {"source_name": "Adjacent normal tissue", "tissue": "adjacent normal esophageal tissue", "tumor_pathological_stage": "NA", "tnm_stage": "NA"}
SRX8208805 Adjacent Normal Esophageal 0.735 16.9 45164 1169.1 103357 2690.4 2940 11487.1 0.995 title: GSM4505859 normal N7 WGBS, Homo sapiens, Bisulfite-Seq; {"source_name": "Adjacent normal tissue", "tissue": "adjacent normal esophageal tissue", "tumor_pathological_stage": "NA", "tnm_stage": "NA"}
SRX8208806 Adjacent Normal Esophageal 0.721 19.0 37384 1181.8 135565 3202.9 2514 9284.9 0.993 title: GSM4505860 normal N8 WGBS, Homo sapiens, Bisulfite-Seq; {"source_name": "Adjacent normal tissue", "tissue": "adjacent normal esophageal tissue", "tumor_pathological_stage": "NA", "tnm_stage": "NA"}
SRX8208807 Adjacent Normal Esophageal 0.729 14.7 37622 1188.1 104579 2943.3 2640 9930.4 0.988 title: GSM4505861 normal N9 WGBS, Homo sapiens, Bisulfite-Seq; {"source_name": "Adjacent normal tissue", "tissue": "adjacent normal esophageal tissue", "tumor_pathological_stage": "NA", "tnm_stage": "NA"}
SRX8208808 Adjacent Normal Esophageal 0.731 17.5 36418 1166.2 104859 3007.3 2779 8548.1 0.994 title: GSM4505862 normal N11 WGBS, Homo sapiens, Bisulfite-Seq; {"source_name": "Adjacent normal tissue", "tissue": "adjacent normal esophageal tissue", "tumor_pathological_stage": "NA", "tnm_stage": "NA"}
SRX8208809 Adjacent Normal Esophageal 0.742 18.2 41829 1171.1 104127 2968.6 3417 9070.6 0.993 title: GSM4505863 normal N12 WGBS, Homo sapiens, Bisulfite-Seq; {"source_name": "Adjacent normal tissue", "tissue": "adjacent normal esophageal tissue", "tumor_pathological_stage": "NA", "tnm_stage": "NA"}
SRX8208810 Adjacent Normal Esophageal 0.732 14.1 38499 1160.6 95634 2631.6 2924 9043.0 0.989 title: GSM4505864 normal N13 WGBS, Homo sapiens, Bisulfite-Seq; {"source_name": "Adjacent normal tissue", "tissue": "adjacent normal esophageal tissue", "tumor_pathological_stage": "NA", "tnm_stage": "NA"}
SRX8208812 Esophageal Squamouse Carcinoma 0.664 18.4 60930 3675.9 197634 5299.3 2432 394772.4 0.995 title: GSM4505866 Tumor T1 WGBS, Homo sapiens, Bisulfite-Seq; {"source_name": "Esophageal Squamouse carcinoma", "tissue": "esophageal squamouse carcinoma", "tumor_pathological_stage": "moderately differentiated", "tnm_stage": "T11N1aM0"}
SRX8208813 Esophageal Squamouse Carcinoma 0.652 18.3 50651 2544.1 228185 5142.1 1101 1102742.1 0.995 title: GSM4505867 Tumor T2 WGBS, Homo sapiens, Bisulfite-Seq; {"source_name": "Esophageal Squamouse carcinoma", "tissue": "esophageal squamouse carcinoma", "tumor_pathological_stage": "highly or moderately differentiated", "tnm_stage": "T11N0M0"}
SRX8208814 Esophageal Squamouse Carcinoma 0.621 17.7 50186 3552.6 169761 8864.1 1849 648741.4 0.995 title: GSM4505868 Tumor T6 WGBS, Homo sapiens, Bisulfite-Seq; {"source_name": "Esophageal Squamouse carcinoma", "tissue": "esophageal squamouse carcinoma", "tumor_pathological_stage": "moderately differentiated", "tnm_stage": "T11N0M0"}
SRX8208815 Esophageal Squamouse Carcinoma 0.574 19.0 68276 7369.4 138765 4569.4 4449 141773.6 0.995 title: GSM4505869 Tumor T7 WGBS, Homo sapiens, Bisulfite-Seq; {"source_name": "Esophageal Squamouse carcinoma", "tissue": "esophageal squamouse carcinoma", "tumor_pathological_stage": "moderately differentiated", "tnm_stage": "T11N0M0"}
SRX8208816 Esophageal Squamouse Carcinoma 0.603 19.1 65565 8949.6 204464 6440.9 2093 604560.0 0.995 title: GSM4505870 Tumor T8 WGBS, Homo sapiens, Bisulfite-Seq; {"source_name": "Esophageal Squamouse carcinoma", "tissue": "esophageal squamouse carcinoma", "tumor_pathological_stage": "highly or moderately differentiated", "tnm_stage": "T2N1aM0"}
SRX8208817 Esophageal Squamouse Carcinoma 0.635 17.3 67273 6557.0 169420 3844.9 2016 559033.8 0.992 title: GSM4505871 Tumor t9 WGBS, Homo sapiens, Bisulfite-Seq; {"source_name": "Esophageal Squamouse carcinoma", "tissue": "esophageal squamouse carcinoma", "tumor_pathological_stage": "highly differentiated", "tnm_stage": "T2N0M0"}
SRX8208818 Esophageal Squamouse Carcinoma 0.635 18.0 71415 4650.5 133694 3604.0 3283 133902.4 0.993 title: GSM4505872 Tumor T11 WGBS, Homo sapiens, Bisulfite-Seq; {"source_name": "Esophageal Squamouse carcinoma", "tissue": "esophageal squamouse carcinoma", "tumor_pathological_stage": "moderately differentiated", "tnm_stage": "T2N0aM0"}
SRX8208819 Esophageal Squamouse Carcinoma 0.672 17.0 40465 1077.1 207221 4430.8 2307 10225.4 0.994 title: GSM4505873 Tumor T12 WGBS, Homo sapiens, Bisulfite-Seq; {"source_name": "Esophageal Squamouse carcinoma", "tissue": "esophageal squamouse carcinoma", "tumor_pathological_stage": "moderately differentiated", "tnm_stage": "T11N1aM0"}

Methods

All analysis was done using a bisulfite sequnecing data analysis pipeline DNMTools developed in the Smith lab at USC.

Mapping reads from bisulfite sequencing: Bisulfite treated reads are mapped to the genomes with the abismal program. Input reads are filtered by their quality, and adapter sequences in the 3' end of reads are trimmed. This is done with cutadapt. Uniquely mapped reads with mismatches/indels below given threshold are retained. For pair-end reads, if the two mates overlap, the overlapping part of the mate with lower quality is discarded. After mapping, we use the format command in dnmtools to merge mates for paired-end reads. We use the dnmtools uniq command to randomly select one from multiple reads mapped exactly to the same location. Without random oligos as UMIs, this is our best indication of PCR duplicates.

Estimating methylation levels: After reads are mapped and filtered, the dnmtools counts command is used to obtain read coverage and estimate methylation levels at individual cytosine sites. We count the number of methylated reads (those containing a C) and the number of unmethylated reads (those containing a T) at each nucleotide in a mapped read that corresponds to a cytosine in the reference genome. The methylation level of that cytosine is estimated as the ratio of methylated to total reads covering that cytosine. For cytosines in the symmetric CpG sequence context, reads from the both strands are collapsed to give a single estimate. Very rarely do the levels differ between strands (typically only if there has been a substitution, as in a somatic mutation), and this approach gives a better estimate.

Bisulfite conversion rate: The bisulfite conversion rate for an experiment is estimated with the dnmtools bsrate command, which computes the fraction of successfully converted nucleotides in reads (those read out as Ts) among all nucleotides in the reads mapped that map over cytosines in the reference genome. This is done either using a spike-in (e.g., lambda), the mitochondrial DNA, or the nuclear genome. In the latter case, only non-CpG sites are used. While this latter approach can be impacted by non-CpG cytosine methylation, in practice it never amounts to much.

Identifying hypomethylated regions (HMRs): In most mammalian cells, the majority of the genome has high methylation, and regions of low methylation are typically the interesting features. (This seems to be true for essentially all healthy differentiated cell types, but not cells of very early embryogenesis, various germ cells and precursors, and placental lineage cells.) These are valleys of low methylation are called hypomethylated regions (HMR) for historical reasons. To identify the HMRs, we use the dnmtools hmr command, which uses a statistical model that accounts for both the methylation level fluctations and the varying amounts of data available at each CpG site.

Partially methylated domains: Partially methylated domains are large genomic regions showing partial methylation observed in immortalized cell lines and cancerous cells. The pmd program is used to identify PMDs.

Allele-specific methylation: Allele-Specific methylated regions refers to regions where the parental allele is differentially methylated compared to the maternal allele. The program allelic is used to compute allele-specific methylation score can be computed for each CpG site by testing the linkage between methylation status of adjacent reads, and the program amrfinder is used to identify regions with allele-specific methylation.

For more detailed description of the methods of each step, please refer to the DNMTools documentation.